RMD

ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 2002

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended June 30, 2002 for ResMed Inc., a leading developer, manufacturer, and distributor of medical equipment for treating sleep disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with manufacturing facilities in Australia and Germany, and executive offices in California. During the fiscal year, ResMed acquired Labhardt Ag (Swiss distributor) and Servo Magnetics Inc. (motor manufacturer) to expand its distribution and product capabilities.

Key Financial Metrics

Debt & Liquidity: The company holds $123.3 million in 4% convertible subordinated notes due 2006. Cash and cash equivalents totaled $72.9 million, with an additional $20.0 million in marketable securities. The company repurchased $56.8 million face value of its convertible notes during the year, recognizing a pre-tax gain of $6.5 million.

Material Changes vs. Prior Period

• Revenue Growth: Driven by increased unit sales of flow generators and accessories in domestic and international markets, as well as the contribution from the MAP acquisition (completed in FY2001).
• Margin Compression: Gross margin declined from 68% to 65% due to a shift in sales mix toward lower-margin domestic sales and the inclusion of MAP's historically lower margins.
• Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 31% to $64.5 million, largely due to headcount growth and a $1.0 million provision for a receivable from American Home Patient Inc. (AHP), which filed for Chapter 11 bankruptcy in July 2002.
• One-Time Items: Net income was significantly boosted by a $6.5 million gain on the extinguishment of debt. Conversely, a $0.4 million write-off of in-process R&D occurred upon the Servo Magnetics acquisition.
• Acquisitions: Completed the acquisition of Servo Magnetics Inc. for $32.6 million (cash and stock) and Labhardt Ag for $5.5 million.

Outlook, Risks, and Management Commentary

• Strategy: Management continues to focus on product innovation (e.g., AutoSet Spirit), geographic expansion, and increasing clinical awareness of SDB. R&D spending increased to $14.9 million (7.3% of revenue).
• Capital Allocation: The company authorized a $4 million share repurchase program, buying back 290,047 shares in FY2002. Significant capital expenditures ($28.2 million) were directed toward a new 30-acre manufacturing site in Sydney, Australia.
• Risks:
  • Reimbursement: Reliance on third-party payers (Medicare, Medicaid, private insurers) creates pricing pressure and reimbursement uncertainty.
  • Competition: Highly competitive market with major players like Respironics and DeVilbiss; risk of product obsolescence.
  • Legal: Ongoing patent litigation against Respironics (summary judgments granted to Respironics, ResMed intends to appeal) and Fisher & Paykel Healthcare.
  • Foreign Exchange: Significant exposure to Australian and European currency fluctuations, managed via hedging programs.

Investor Verification Checklist

• Debt Conversion Risk: Verify the status of the $123.3 million convertible notes and the potential dilution if the stock price exceeds the conversion price of $60.60.
• Customer Concentration: Assess the impact of the American Home Patient Inc. (AHP) bankruptcy on future receivables and revenue stability.
• Acquisition Integration: Monitor the integration progress and margin performance of the newly acquired Servo Magnetics and Labhardt entities.
• Patent Litigation: Track the outcome of the appeal regarding the Respironics patent infringement case, as a loss could impact competitive positioning.
• Reimbursement Policy Changes: Watch for legislative or payer changes affecting CPAP device reimbursement rates in the U.S. and key European markets.